Edwards Lifesciences backs FY24 constant currency sales growth of 8%-10%

FY24 consensus $5.83B. “It is an exciting day for Edwards as we share our vision for 2025 and how our talented team and focus in structural heart is enabling us to help even more patients,” said Bernard Zovighian, Edwards’ CEO. “We are projecting another year of strong total company sales growth of 8 to 10 percent. We have significant opportunities to grow TAVR and are proud to continue our deep commitment to advancing science and streamlining care for aortic stenosis patients. Our vision for TMTT has developed into a growth portfolio of differentiated technologies. In Surgical, we continue to see strong global adoption of our premium RESILIA technologies.” Zovighian continued, “In 2026 and beyond, strong total company sales growth will be driven by meaningful catalysts with the potential to change aortic stenosis treatment, including EARLY TAVR and the expected successful outcome from the FDA-approved PROGRESS pivotal trial. TMTT’s portfolio of life-changing therapies including PASCAL, EVOQUE and SAPIEN M3 will drive multiple years of rapid growth, while AR and Structural Heart Failure will address two new significant patient opportunities.”